We analyzed and compared 1-(2 -deoxy-2 -fluoro-D-arabinofuranosyl)-[methyl-11C]thymine (11C-FMAU), 3 -deoxy-3 -[18F]fluorothymidine (18F-FLT) and 1-(2 -deoxy-2 -fluoro-D-arabinofuranosyl)-5-[76Br]bromouracil (76Br-BFU) with respect to tissue uptake, DNA incorporation, and excretion modulation in rats. The goal of the investigation was to evaluate the efficiency of the 3 nucleoside tracers as po...

More than 30 years ago, Judah Folkman hypothesized that tumor angiogenesis could be a target of anticancer therapy. Some of the initial studies were actually performed in patients with glioblastomas, which had the greatest extent of tumor angiogenesis among a variety of human malignancies. The identification of vascular endothelial growth factor (VEGF) also provided a firm foundation for the de...

PURPOSE We describe a noninvasive PET imaging method that monitors early therapeutic efficacy of BAY 87-2243, a novel small-molecule inhibitor of mitochondrial complex I as a function of hypoxia-inducible factor-1α (HIF1α) activity. EXPERIMENTAL DESIGN Four PET tracers [(18)F-FDG, (18)F-Fpp(RGD)2, (18)F-FLT, and (18)F-FAZA] were assessed for uptake into tumor xenografts of drug-responsive (H4...

Medical imaging plays an important role in radiotherapy. Dose painting consists in the application of a nonuniform dose prescription on a tumoral region, and is based on an efficient segmentation of biological target volumes (BTV). It is derived from PET images, that highlight tumoral regions of enhanced glucose metabolism (FDG), cell proliferation (FLT) and hypoxia (FMiso). In this paper, a fr...

UNLABELLED The use of radiolabeled thymidine (TdR) and thymidine analogs as PET-based tracers of tumor growth rate is based on the assumption that measurement of uptake of these nucleosides, a function primarily of thymidine kinase-1 (TK(1)) activity, provides an accurate measure of active cell proliferation in tumors. The goal of this study was to test this hypothesis and determine how well th...

Positron emission tomography (PET) is being increasingly used for the evaluation of patients with known or suspected cancer at all phases of the management process from diagnosis, through staging to follow-up after treatment. The role of PET in therapeutic monitoring is expanding rapidly due to its ability to provide earlier and more robust identification of non-responders than provided by conv...